# This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse Effects

> **NCT07676669** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Watim Medical & Dental College** · enrollment: 140 (estimated)

## Conditions studied

- Bipolar 1 Depression

## Interventions

- **DRUG:** Lumateperone
- **DRUG:** Cariprazine

## Key facts

- **NCT ID:** NCT07676669
- **Lead sponsor:** Watim Medical & Dental College
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2027-03
- **Final completion:** 2027-08
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07676669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07676669, "This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse Effects". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07676669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*